Pharma News

Intercharm Moscow 2023 was held from 25th - 28th October 2023 at Crocus Expo, Moscow, Russian Federation. This was 29th International exhibition for perfumery and cosmetics industry.

Sun Pharmaceutical Industries Limited and Zydus Lifesciences Limited announced that both companies have entered into a licensing agreement to co-market an innovative drug, Desidustat in India. Desidustat is first-of-its-kind oral treatment for anemia associated with Chronic Kidney Disease (CKD) in India.

T cells are soldiers on the front lines of the human immune system. They are responsible for many important roles, including attacking viral- or bacterial-infected cells and certain cancer cells, and immunological memory – remembering the specific pathogens or the cancer signatures that originally trigger T cells.

Psoriasis - a chronic skin condition - is not caused or spread by spontaneous genetic mutations in the skin, new research suggests. The team, from the Wellcome Sanger Institute and collaborators, sequenced skin samples from 111 people with psoriasis. They didn’t find any mutated genes in the psoriatic patches that weren’t also mutated in the individual’s unaffected skin tissue.

Study synopsis
- The trial was presented on October 25, 2023 in the PCI Outcomes III session in San Francisco.
- 1835 patients were studied across 19 study centres in UK

SMT (Sahajanand Medical Technologies), a pioneering healthcare company in India with a focus on innovative patient care in the cardiovascular sector, is pleased to announce promising data from its study, the Prospective S-FLEX UK-II Registry.

Eisai Co., Ltd and Biogen Inc. announced today that Eisai presented new data for LEQEMBI® (lecanemab-irmb) 100 mg/mL injection for intravenous (IV) use, in the Late Breaking Symposium 4 Lecanemab for Early Alzheimer's Disease: Long-Term Outcomes, Predictive Biomarkers and Novel Subcutaneous Administration" at the 16th annual Clinical Trials on Alzheimer's Disease (CTAD) conference held in Boston, Massachusetts, United States and virtually October 24-27, 2023.

Scientists at The University of Toledo have proven that engineered bacteria can lower blood pressure, a finding that opens new doors in the pursuit of harnessing our body’s own microbiome to treat hypertension. The study, published this month in the peer-reviewed journal Pharmacological Research, represents a paradigm shift, said Dr. Bina Joe, a hypertension researcher at UToledo and the paper’s senior author.

Mount Sinai researchers have discovered a link between certain per- and polyfluoroalkyl substances (PFAS) and an increased risk for thyroid cancer, according to a study published in eBioMedicine today.

The Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen) announced today promising data from a Phase 2a human challenge study evaluating JNJ-1802, a first-in-class oral antiviral in development for the prevention of dengue. The data showed that the compound induced antiviral activity against dengue (DENV-3) in humans, compared to placebo, and is safe and well-tolerated. The data were announced at the American Society of Tropical Medicine & Hygiene Annual Meeting in Chicago, Illinois.